Precemtabart tocentecan not checked
EMD Serono Research & Development Institute, Inc. · M9140
FollowEvery change as it happens, and a Monday email
Trials
5 active
6 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- How it’s given
- “Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle.”In the company’s words, NCT07549412 on ClinicalTrials.gov
- Tested for
- Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer
- Main trialPhase 3
- “This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluridine/tipiracil (FTD-TPI) plus bevacizumab.”In the company’s words, NCT07549412 on ClinicalTrials.gov
- Other names
- M9140 · Precem-TcT
Other drugs for Metastatic Colorectal Cancer
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up2
- 23 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 16 Oct 2029Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 12 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT06806046
- 12 NovCompletion date moved: 2026-09-30 to 2026-09-23 · ClinicalTrials.gov NCT06806046
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 16 Oct 2029 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | |
| Phase 1/2Active, not recruiting | 23 Dec 2027 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | |
| Phase 1Active, not recruiting | 23 Oct 2026 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | |
| Phase 1Completed | 23 Sep 2026 | Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors | |
| Phase 1/2Authorised | not given | PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC) | |
| Phase 1/2Authorised | not given | PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Pancreatic Cancer (Substudy PDAC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026